Welcome to the Starpharma Investor CentreStarpharma Holdings Limited is an Australian stock exchange listed biotechnology company with products based on its dendrimer technology platform. |
 |
|
|
Latest News & Announcements
Investor Webinar - Starpharma and Medicxi Partnership: Petalion Therapeutics (9 April 2024)
Apr 10th, 2024
Starpharma hosted an investor webinar on Tuesday, 9 April 2024. The session focused on the ASX Announcement lodged on 8 April 2024, 'Starpharma and Medicxi Partnership Petalion Therapeutics', about the strategic partnership with Medicxi and the formation of a new company called Petalion Therapeutics.
Read More
Investor Webinar Notification – Starpharma x Medicxi Partnership (ASX Announcement)
Apr 8th, 2024
Starpharma (ASX: SPL, OTCQX: SPHRY) is pleased to announce that it will host an investor webinar on Tuesday, 9 April 2024.
Read More
Reports & Presentations
Click here for financial reports archive
Which ASX companies are resurrecting abandoned drugs? Part 3
Apr 18th, 2024
"SPL has developed its proprietary Dendrimer Enhanced Products platform (DEP) to improve the effectiveness and safety of drugs, especially cancer treatments." Read the full article in Stockhead.
Read More
Which ASX companies are resurrecting abandoned drugs? Part 3
Apr 18th, 2024
DEP is based on dendrimers, which are highly branched polymers, to enhance the delivery of cancer treatments and reduce toxic side effects such as neutropenia, nausea, severe diarrhoea and hair loss from chemotherapy agents. Read the full article in The Australian Business Review.
Read More